ENDOMETRIAL CANCER

This early-phase study tested a new drug called PHN-010, which delivers a powerful toxin directly to cancer cells. It involved 26 adults with advanced lung, colon, endometrial, ovarian, or cervical cancers that had already been treated. The main goals were to check safety and fin…

This study tested a new drug called BLU-222 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, so results are limited.

This study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women whose endometrial cancer had returned. Only 4 participants were enrolled before the study was stopped early. The goal was to measure how many patients responded…

This early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested a radioactive drug called [225Ac]-FPI-1434 in people with advanced solid tumours that had not responded to standard treatments. The goal was to find a safe dose and see if it could shrink tumours. The trial was stopped early, so results are limited. Participants…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique mutations in their cancer. It was designed for people with advanced solid tumors like lung, pancreatic, or ovarian cancer who had not responded to s…

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if niraparib could shrink tumors or slow their growth. The study was stopped ear…

This study aimed to see if taking letrozole after standard treatment could help prevent endometrial cancer from coming back. It was designed for women with a specific type of cancer (non-specific molecular profile) who had surgery. However, the trial was stopped early and only en…

This early-phase study tested an experimental oral drug called ATX-559 in 17 people with advanced solid tumors (like breast, colon, or endometrial cancer) that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The stu…

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced endometrial or ovarian cancers that are hormone receptor-positive and have certain gene changes (PI3K/PTEN). The goal was to see if the combination was safe and effective. Only 7 peo…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study looked at 92 women with high-risk endometrial cancer who needed pelvic radiation after surgery. It compared a newer, more precise radiation method (IMRT) with the standard 3D technique to see if it could reduce side effects like bowel and bladder problems. The goal was…